Contact Us

Medtronic Infuse Bone-Growth
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

   * Phone 

Cell Phone 

Date when device was implanted :

Please describe any problems or injuries caused by the product:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Medtronic Infuse Bone Growth Use

Medtronic Infuse Side Effects Lawsuits | Medtronic Infuse Bone Graft | Lawyers, Lawsuits | Side Effects: Acute Severe Swelling, Severe Neck Swelling, Inflammed Tissue Difficulty Swallowing, Difficulty Breathing, Difficulty Speaking, Speech Impaired, Uncon

AddThis Social Bookmark Button

Medtronic Infuse Side Effects Lawsuits

Medtronic Infuse Bone Graft | Lawyers, Lawsuits | Side Effects: Acute Severe Swelling, Severe Neck Swelling, Inflammed Tissue Difficulty Swallowing, Difficulty Breathing, Difficulty Speaking, Speech Impaired, Uncontrolled Bone Growth, Ectopic Bone Growth, Nerve Injuries, Severe Pain, Chronic Pain, Chronic Radiating Pain, Chronic Radiating Leg Pain, Chronic Radiating Arm Pain, Neuritis, Radiculopathy,  Radiculitis, Male Sterility, Retrograde Ejaculation, Uro-Genital Injuries Swelling,


Medtronic Infuse Bone Graft Physician Labeling
Medtronic Infuse Bone Graft Application Data
Medtronic Infuse Bone Graft PMA Letter from Department of Health & Human Services

Medtronic Infuse Off-Label Use Lawsuit

Off-label use of Medtronic Inc.’s Infuse bone graft product in cervical spine surgeries, as well as lateral approach or posterior approach spinal procedures, has been linked to serious, and even life threatening side-effects. Some of these Medtronic Infuse injuries include ectopic or uncontrolled bone growth at or near the site of the surgery; ongoing or chronic radiating pain in the legs or arms; male sterility, retrograde ejaculation, or other uro-genital injuries; nerve injuries causing severe and chronic pain; and even cancer. In cervical spine surgeries, an off-label use of Infuse, some patients experience acute severe neck swelling several days after surgery resulting in death or permanent injury. Medtronic has been accused in lawsuits of aggressively promoting unapproved uses of Infuse, and it has also been alleged that research sponsored by the device maker downplayed many serious Infuse bone graft side effects.

Our defective medical device lawyers are aggressively investigating these allegations, and would like to hear from anyone who suffered a serious Infuse bone graft complication. If you sustained a serious injury after undergoing an off-label Medtronic Infuse procedure, you may be eligible for compensation for your medical bills, lost wages, and pain and suffering. We are currently offering free legal consultations to anyone interested in filing a Medtronic Infuse lawsuit. If you or a loved one were injured due to a procedure where this product was used inappropriately, it is vital you contact our Medtronic Infuse lawyers as soon as possible to protect your legal rights.

Medtronic Infuse Off-Label Use Complications

Medtronic Infuse, which contains rhBMP-2 (recombinant human Bone Morphogenetic Protein-2, a protein that stimulates bone growth), was approved by the U.S. Food & Drug Administration (FDA) for use in a type of spine surgery called anterior approach lumbar fusion. This is the ONLY type of spine surgery for which Infuse is approved, though the FDA did later grant clearance for its use in two types of dental surgeries. Despite its limited approval, it has become clear that Infuse bone graft is frequently used off-label in other spine procedures, especially cervical (neck) spine surgery, as well as in lateral approach (through the side of the body) or posterior approach (through the back of the body) spinal procedures. Unfortunately, it has also become apparent that such off-label use puts patients at risk for serious, and even life-threatening, injuries.

Injures linked to off-label use of Infuse bone graft include:

  • Acute severe swelling of the neck several days after surgery, resulting in death or permanent injury;
  • Cancer – may types including stomach, thyroid, breast, skin (melanoma), ovarian, lung, leukemia, prostate, laryngeal, lymphoma, pancreatic;
  • Difficulty swallowing;
  • Difficulty breathing
  • Difficulty speaking
  • Ectopic or uncontrolled bone growth at or near the site of the surgery (a study found that 75% of Infuse patients experienced ectopic bone growth)
  • Nerve injuries causing severe and chronic pain;
  • Ongoing or chronic radiating pain in the legs or arms (i.e., neuritis, radiculopathy, or radiculitis);
  • Male sterility (Independent researchers at Stanford University found evidence that Infuse was linked to a complication that causes sterility in men)
  • Retrograde ejaculation, or other uro-genital injuries in male patients.

In 2008, the FDA warned Infuse bone graft and similar products had caused serious problems when they were used off-label in cervical spine surgeries. At the time, the agency said that it had received dozens of reports of side effects linked to off-label Infuse procedures, mainly swelling of neck and throat tissue, which resulted in compression of the airway and other structures in the neck. Patients reported difficulty swallowing, breathing and speaking. Several required emergency treatment, including tracheotomies and the insertion of feeding tubes, as well as second surgeries.

In November 2008, Medtronic disclosed that the U.S. Department of Justice (DOJ) was investigating the off-label use of a Medtronic's Infuse bone graft. According to a report from The Wall Street Journal, at least 280 reports of side effects involving Infuse had been made to the FDA when the investigation was announced. About three-quarters of those reports involved off-label use. While doctors are permitted to use approved medical devices in any way they see fit, it is illegal for manufacturers to market products based on such uses.

Did Medtronic Downplay Infuse Side Effects?

Plaintiffs in Infuse bone graft lawsuits allege that Medtronic either negligently or fraudulently misrepresented the risks and benefits of Infuse. In June 2011, such allegations were given credence by a study published in The Spine Journal which disclosed that Medtronic-paid researchers had failed to report serious complications from Infuse, including cancer, sterility in men, infections, bone dissolution and worsened back and leg pain. The article said these complications occurred in 10 to 50 percent of patients who got the product in 13 Medtronic-funded clinical trials conducted between 2000 and 2010. The Spine Journal review also examined payment data from Medtronic to the doctors who co-authored the Infuse studies, and found that the median amount the company paid to doctors was at least $12 million to $16 million per study (though it should be noted that none of the royalty payments related to Infuse.)

Legal Help for Victims of Medtronic Infuse Off-Label Complications

If you or someone you know sustained an injury due to off-label use of the Medtronic Infuse bone graft, you have valuable legal rights. To learn how our Medtronic Infuse lawyers can help you, please fill out our online form, or call 1-800 LAW INFO (1-800-529-4636) to discuss your case with one of our experienced Medtronic Infuse Bone Graft lawyers.

Latest Medtronic Infuse Bone Graft News:


June 28, 2011: Medtronic Clinical Trials showed Infuse Bone Graft Issues

June 22, 2011: Medtronic Infuse Bone Graft Studies under Congressional investigation for possible payments to Orthopaedic Surgeons to hide serious side effects

Tags:  
Medtronic Infuse Bone Growth UseRSS Feed

Medtronic Attributes Drop in Spinal Revenue to Decline in Infuse Sales

Feb 21, 2012 | Parker Waichman LLP
A study presented this past November might be, at least partially, responsible for yet another drop in the sales of Medtronic Inc.'s Infuse bone graft product.  The company announced today that revenues from sales of its spinal products dropped 9% in the third quarter ending January 27, mostly due to a decline in Infuse sales.Infuse sales have been on a downward track recently, not surprising when you consider the controversy that has swirled around the genetically engineered bone growth...

Medtronic Infuse Controversy Opens Door for Competitors

Feb 14, 2012 | Parker Waichman LLP
With Medtronic Inc's sales of its Infuse bone growth product taking a hit thanks to recent controversies surrounding its possible side effects, several companies could find new markets for their spinal fusion products, according to a report from MedCity News.  As we've reported previously, Medtronic is facing a mountain of legal trouble over Infuse, including several product liability lawsuits claiming it caused serious complications in patients.  Over the summer, The Spine Journal...

Medtronic Infuse Shareholder Lawsuit Witness Must Testify, Judge Says

Feb 3, 2012 | Parker Waichman LLP
A former Medtronic Inc. employee won't be able to avoid testifying in a shareholder lawsuit involving the device maker's alleged illegal promotion of off-label uses for its Infuse bone graft product.  Yesterday, a federal judge in Minnesota ordered the unnamed witness to testify and turn over a key Infuse document, ruling that he had waived his 5th Amendment protections.In August 2009, the Minneapolis Firefighters’ Relief Association and other institutional investors alleged in an...

Cancer, Other Safety Worries Point to Dim Future for Medtronic Infuse

Feb 2, 2012 | Parker Waichman LLP
Medtronic Inc.'s sales of its Infuse (rhBMP-2) product have taken a hit in recent months, thanks to concerns that the bone growth protein may be associated with cancer and other serious side effects.  Now one analyst is raising doubts as to whether Medtronic can salvage Infuse and convince doctors to start to start using it again."Someone who is a very poor healer, someone who is in a revisional surgery, someone who is older and not in child-bearing age … some doctors still see an...

Medtronic Infuse Concerns Prompt Questions from Senators

Dec 19, 2011 | Parker Waichman LLP
Medtronic Inc. is taking more heat over its controversial Infuse bone graft product.  Now, three U.S. Senators are asking questions about Infuse, and want to know if research for the bone growth protein downplayed serious side effects, including cancer, associated with it. Infuse is a recombinant human Bone Morphogenetic Protein (rhBMP-2) that is widely used in spinal fusion surgery.  However, it has only been approved by the U.S. Food & Drug Administration (FDA) for use in...

More Medtronic Infuse Bone Growth Use News